Molecular subtyping combined with multiomics analysis to study correlation between TACE refractoriness and tumor stemness in hepatocellular carcinoma

被引:0
|
作者
He, Qifan [1 ]
Xiong, Yue [1 ]
Yang, Xiaoyu [1 ]
Yu, Yihui [1 ]
Chen, Zhonghua [1 ]
机构
[1] Haining Peoples Hosp, Dept Radiol, 2 Qianjiang West Rd, Haining 314400, Peoples R China
关键词
Hepatocellular carcinoma; TACE refractoriness; Tumor stemness; Multi-omics analysis; Clinical study; Molecular subtyping; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; LIVER-CANCER; TRANSARTERIAL CHEMOEMBOLIZATION; CELLS; IMMUNOTHERAPY; PLATFORM; ATLAS;
D O I
10.1007/s12672-025-01955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTransarterial chemoembolization (TACE) refractoriness is a significant challenge in treating intermediate to advanced-stage hepatocellular carcinoma (HCC). A few studies suggest that liver cancer stem cells (LCSCs) may be associated with TACE refractoriness. This study aims to explore the potential correlation between TACE refractoriness and HCC stemness, highlighting its clinical significance.MethodsThis research encompassed the analysis of diverse HCC datasets, including RNA-sequencing, microarray, single-cell RNA-sequencing, and clinical cohorts. We identified common genes between TACE refractoriness and tumor stemness (TSGs). Unsupervised clustering was employed to classify HCC patients into different clusters based on TSGs (TRS clusters). The study explored the differences in clinical prognosis, biological characteristics, genomic variations, immune landscapes, and treatment responses among the TRS clusters.ResultsPatients with TACE-refractoriness demonstrated significantly higher tumor stemness. Our study identified 33 TSGs and established two TRS clusters, including C1 and C2. C1 was associated with TACE refractoriness, elevated tumor stemness, and poorer prognosis. Genomic alterations were found to be significantly different between the TRS clusters. The C1 exhibited signs of immunosuppression and lower activity of immune effector cells, while the C2 had a more robust immune response and higher level of immune cell presence. Single-cell RNA-seq revealed distinct cell type characteristics in each subtypes, with the C1 showing a higher proportion of stem cells and malignant cells.ConclusionOur findings establish a connection between TACE refractoriness and tumor stemness in HCC, proposing a novel subtype classification to guide personalized treatment. Insights gained may facilitate overcoming TACE refractoriness and the development of innovative therapies.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Survival analysis of sorafenib combined with TACE in hepatocellular carcinoma patients
    Cao, Jingqin
    Zhang, Defen
    Zhang, Yingchun
    Yue, Yanxiao
    Cai, Huaizhuang
    Zhang, Jie
    Wang, Zuoxiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (09): : 6823 - 6828
  • [2] Integrative analysis of tumor stemness and immune microenvironment deciphers novel molecular subtypes in hepatocellular carcinoma
    Wang, Zhiyi
    Weng, Siyuan
    Li, Dongxiao
    Xu, Hui
    Chen, Shuang
    Zhang, Yuyuan
    Ren, Yuqing
    Guo, Chunguang
    Li, Xiuling
    Liu, Zaoqu
    Han, Xinwei
    GENES & DISEASES, 2024, 11 (05)
  • [3] A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
    Li, Xiaomi
    Ding, Xiaoyan
    Liu, Mei
    Wang, Jingyan
    Sun, Wei
    Teng, Ying
    Xu, Yawen
    Wu, Hongxiao
    Li, Wendong
    Zhou, Lin
    Chen, Jinglong
    CANCER MEDICINE, 2023, 12 (16): : 16805 - 16814
  • [4] Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma
    He, Qifan
    Yang, Jian
    Jin, Yonghai
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma
    Yang, Shuai
    Zheng, Lu
    Li, Lingling
    Zhang, Jiangang
    Wang, Jingchun
    Zhao, Huakan
    Chen, Yu
    Liu, Xudong
    Gan, Hui
    Chen, Junying
    Yan, Mei
    He, Chuanyin
    Li, Kai
    Ding, Chen
    Li, Yongsheng
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (06):
  • [6] Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
    Zhang, XiuPing
    Wang, Kang
    Wang, Meng
    Yang, Guang
    Ye, XiaoFei
    Wu, MengChao
    Cheng, ShuQun
    ONCOTARGET, 2017, 8 (17) : 29416 - 29427
  • [7] Transarterial chemoembolization (TACE) combined with Sorafenib is more effective than TACE for hepatocellular carcinoma with portal vein tumor thrombus
    Zhang, Ze-Han
    Zhu, Hui-Min
    Zhou, Teng-Fei
    Li, Nan
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S544 - S546
  • [8] Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
    Qiu, Zhiyu
    Shen, Lujun
    Jiang, Yiquan
    Qiu, Jiliang
    Xu, Zining
    Shi, Mengting
    Yu, Zhentao
    Ma, Yanping
    He, Wei
    Zheng, Yun
    Li, Binkui
    Wang, Guoying
    Yuan, Yunfei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (04)
  • [9] Survival benefit of TACE combined with sorafenib for hepatocellular carcinoma patients with portal vein tumor thrombus
    Luo, Bin
    Chen, Zhen-Hua
    Zhang, Xiu-Ping
    Wang, Meng
    Cheng, Shu-Qun
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S293 - S295
  • [10] Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study
    Nahm, Ji Hae
    Rhee, Hyungjin
    Kim, Haeryoung
    Yoo, Jeong Eun
    Lee, Jee San
    Jeon, Youngsic
    Choi, Gi Hong
    Park, Young Nyun
    ONCOTARGET, 2017, 8 (59) : 99359 - 99371